Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC).

Background: OPC is a once-daily COMT inhibitor that proved effective in the treatment of motor fluctuations in PD patients in two large, pivotal, multinational trials (BIPARK-I and II) [1],[2].

Method: Patient-level data from matching treatment arms in BIPARK-I and II were combined in placebo (PLC) and OPC-50mg groups. The studies had similar designs (primary efficacy endpoint: change from baseline in patient diaries-based absolute OFF-time) and eligibility criteria [1],[2]. Safety was assessed by incidence of TEAEs, laboratory parameters, ECGs and vital signs. An exploratory post-hoc analysis was performed to evaluate the incidence of TEAEs according to gender.

Results: Of the 1027 patients randomized to BIPARK-I and II, 522 patients took a dose of study medication (OPC-50mg n=265, PLC n=257) and were included in this analysis. Male patients represented ~58% of both OPC-50mg and PLC groups. Overall, 64.2% of OPC-50mg patients reported any TEAE compared to 57.2% in PLC. There was a comparable incidence of TEAEs for Male-matched user patients (65.0% vs. 56.3% for OPC-50mg and PLC groups) and Female-matched patients (62.9% vs. 58.3% for OPC-50mg and PLC groups). The most frequently occurring TEAE was dyskinesia in both subgroups.

Conclusion: Opicapone appears to be equally well-tolerated in both Male and Female patients.

References: [1] Ferreira et al., Lancet Neurology 2016; 15(2):154-165. [2] Lees et al., JAMA Neurol. 2017; 74(2):197-206.

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/incidence-of-treatment-emergent-adverse-events-in-parkinsons-disease-patients-according-to-gender-post-hoc-analysis-from-double-blind-combined-bipark-i-and-ii-data/